Hyperammonemia associated with valproic acid concentrations.

Area of Science:

• Pharmacology
• Biochemistry
• Clinical Toxicology

Background:

• Valproic acid (VPA) is a broad-spectrum anticonvulsant used for epilepsy and bipolar disorder.
• VPA is metabolized in the liver via mitochondrial beta-oxidation, requiring carnitine for transport.
• High-dose or overdose VPA can lead to carnitine depletion and hyperammonemia.

Purpose of the Study:

• To investigate the potential of salivary VPA levels as a monitoring tool.
• To explore the relationship between VPA, carnitine depletion, and hyperammonemia.
• To identify therapeutic strategies for managing VPA-induced hyperammonemia.

Main Methods:

• Correlation analysis of salivary VPA levels with plasma ultrafiltrate levels in humans.
• Review of VPA metabolism and carnitine's role in mitochondrial transport.
• Evaluation of proposed therapeutic interventions.

Main Results:

• A significant correlation was observed between salivary and plasma VPA levels.
• Carnitine depletion is a key factor in VPA-induced hyperammonemia.
• Extended-release VPA formulations and carnitine supplementation are potential countermeasures.

Conclusions:

• Saliva is a viable and promising fluid for monitoring VPA pharmacokinetics and toxicity.
• Managing carnitine levels is crucial in preventing or treating VPA-induced hyperammonemia.
• Therapeutic strategies exist to mitigate the toxic effects of VPA.